PR Newswire HANGZHOU, China, April 22, 2025 HANGZHOU, China, April 22, 2025 /PRNewswire/ -- Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic ...
PR Newswire TOKYO, April 23, 2025 TOKYO, April 23, 2025 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today an investment of approximately JPY 679 million (USD 4.5 million1) for the development of diagnostics ...
PR Newswire HONG KONG, April 22, 2025 - ASC30 oral once-daily tablet demonstrated a 6.5% placebo-adjusted mean body weight reduction from baseline after four-week treatment using weekly doses with titrations of 2 mg, 10 mg, 20 mg, and 40 mg ...
PR Newswire WASHINGTON, April 21, 2025 Nearly 1/4 of American Adults Say They are Likely to Use Cannabis as a Sleep Aid WASHINGTON, April 21, 2025 /PRNewswire/ -- Today National Sleep Foundation (NSF) releases new data on the public's ...
PR Newswire PARAMUS, N.J., April 21, 2025 PARAMUS, N.J., April 21, 2025 /PRNewswire/ -- NS Pharma, Inc. (NS Pharma) a subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku), announced today that the U.S. Food & Drug Administration (FDA) ...
PR Newswire PITTSBURGH, April 21, 2025 Aiming to address a significant unmet need for which no other approved treatment option is available for generalized anxiety disorder patients in Japan PITTSBURGH, April 21, 2025 /PRNewswire/ ...
PR Newswire LONDON, April 17, 2025 LONDON, April 17, 2025 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces it has acquired the FDA-approved Abbreviated New Drug Application (ANDA) ...
PR Newswire INDIANAPOLIS, April 17, 2025 Orforglipron is the first small molecule GLP-1 to successfully complete a Phase 3 trial, lowering A1C by an average of 1.3% to 1.6% across doses The investigational once-daily oral pill reduced ...
PR Newswire TAIPEI, April 17, 2025 TAIPEI, April 17, 2025 /PRNewswire/ -- Caliway Biopharmaceuticals (TWSE: 6919) announced today that it has been invited to present the clinical results of its CBL-514 Phase 2 study (CBL-0201DD) in Dercum's ...
PR Newswire CHINO, Calif., April 17, 2025 CHINO, Calif., April 17, 2025 /PRNewswire/ -- SEBiotic® (Bacillus coagulans LBSC), produced by Specialty Enzymes & Probiotics, is a spore-forming probiotic shown to be effective and safe in the ...
Lecanemab use is higher among white, male, urban, and wealthier patients despite broad Medicare coverage.
New antifungal nanotechnology uses targeted liposomes to boost drug delivery and fight Candida infections.
Real-world evidence shows long-term use of oral and inhaled steroids increases the risk of adrenal insufficiency, highlighting the need for proper treatment alternatives.
Legalizing and increased consumption of cannabis has led to increased cases of people visiting hospitals, many due to anxiety, psychosis, and other mental health disorders.
Glucagon-like peptide-1 receptor agonists improve cardiovascular outcomes and reduce mortality in patients with type 2 diabetes.
Subscribe to our Free Newsletters!
Medindia's policies are aligned with the United Nations Sustainable Development Goals (SDGs) - SDG 3, SDG 4, SDG 5, SDG 6 , SDG 10 & SDG 12.
Disclaimer - All information and content on this site are provided for informational and educational purposes only. They should NOT be used for the diagnosis or treatment of any health-related condition or disease. Always consult a qualified healthcare professional for medical advice, diagnosis, or treatment. Full Disclaimer
Advertise with us | Medindia Copyright | Privacy Policy | Terms of Use © All Rights Reserved 1997 - 2025
Careers